Developer docs
API playgroundTry for free, no card

Search company profiles

Factor Bioscience

Full company profile

uuid0006eko

Namestring
Factor Bioscience
Legal namestring
Factor Bioscience Inc.
Websiteurl
factorbio.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Factor Bioscience Inc. is a privately held, pre-clinical biotechnology company headquartered in Cambridge, Massachusetts, founded in 2011 with 1-10 employees. The company develops gene-edited cell therapies built on an integrated platform of patented mRNA, cell-reprogramming, and gene-editing technologies developed over approximately 15 years. Its active programs include FACT-112, an IL12-expressing iMacrophage candidate designed to repolarize immunosuppressive tumor microenvironments in solid tumors such as ovarian cancer; iPSC-derived mesenchymal stem cells targeting muscular dystrophy and neurodegenerative disorders; and gene-edited hypoimmune iPSC cell lines designed to reduce immunogenicity across cell therapy indications.

The company's scientific activities are evidenced by seven presentations at the ASGCT 29th Annual Meeting (Boston, May 2026) and pre-clinical data at ISCT 2026 (Dublin). In February 2026, Factor divested four dual-targeting CAR-T programs, including the clinical-stage CD19/BCMA candidate TPST-2003, to Tempest Therapeutics in an all-stock transaction, with co-founder Dr. Matt Angel departing to become President and CEO of Tempest. Factor retains operational independence and continues to advance the remaining platform programs.

Factor Bioscience operates as a technology licensor and platform provider rather than a direct commercial developer. Revenue mechanics consist of non-dilutive grant funding (including a U.S. Department of Defense grant awarded in January 2024 for Duchenne muscular dystrophy research) and partnership milestone/option payments (including a success payment from Lineage Cell Therapeutics in January 2026 tied to a hypoimmune iPSC cell line delivery). Pricing is not publicly disclosed and the company is pre-revenue, with no disclosed institutional venture financing. Customers and partners to date include the U.S. Department of Defense, Lineage Cell Therapeutics, and Tempest Therapeutics.

Short descriptiontext

Factor Bioscience is a pre-clinical Cambridge, Massachusetts biotechnology company developing gene-edited cell therapies on a patented mRNA, cell-reprogramming, and gene-editing platform, targeting solid tumors, muscular dystrophy, and neurodegenerative disorders via licensing and partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene-editing technology, mRNA cell engineering, iPSC cell therapy, regenerative medicine, cell reprogramming
Industry3 codes
PRIMARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Medicine Cell Therapy
Social media profiles1 record
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Factor Bioscience develops an integrated platform of patented mRNA, cell-reprogramming, and gene-editing technologies for creating scalable, off-the-shelf gene-edited cell therapies. Its pipeline includes IL12-expressing iMacrophages (FACT-112) for solid tumors, iPSC-derived mesenchymal stem cells for muscular dystrophy and neurodegenerative disorders, dual-targeting CAR-T programs, and hypoimmune iPSC cell lines licensed to partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 100% complete response rate observed in CAR-T-naïve patients treated with TPST-2003 across REDEEM-1 and POEMS-1 trials (data generated by acquirer Tempest Therapeutics)
+1 more record
Product overview1 text field

Factor Bioscience is a Cambridge, Massachusetts-based biotechnology company that has developed a proprietary platform of patented mRNA, cell-reprogramming, and gene-editing technologies. The company operates multiple engineered cell therapy programs including: FACT-112 (IL12-expressing iMacrophages for solid tumors), iPSC-derived Mesenchymal Stem Cells for muscular dystrophy and neurodegenerative disorders, and Next-Generation CAR-T Approaches featuring dual-targeting technologies. The platform is built on 15 years of development in RNA-enabled cell engineering, with off-the-shelf cell therapy capabilities. The company also developed hypoimmune iPSC cell lines through partnerships.

Product and service5 records
1FACT-112 (IL12-expressing iMacrophages)
CategoryCell Therapy - Oncology
2iPSC-derived Mesenchymal Stem Cells
CategoryCell Therapy - Regenerative Medicine
3Next-Generation Dual-Targeting CAR-T Programs
CategoryCell Therapy - Hematological Oncology
4RNA-Enabled Cell Engineering Platform
CategoryBiotechnology Platform
5Gene-Edited Hypoimmune iPSC Cell Line
CategoryCell Therapy - Engineered Cell Line
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-06
Description

Strategic collaboration where Lineage Cell Therapeutics received a novel gene-edited hypoimmune iPSC cell line from Factor Bioscience. Acceptance of the cell line triggered a success payment from Lineage to Factor. Lineage retains an option to obtain an exclusive license for preclinical, clinical, and commercial use of the cell line. The cell line contains specific edits designed to reduce immunogenicity and prevent adverse immune responses across a range of cell therapy indications.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-19
Description

All-stock acquisition of four dual-targeting CAR-T programs from Factor Bioscience and Erigen LLC by Tempest Therapeutics. Following the transaction, Factor's co-founder Dr. Matt Angel became President and CEO of Tempest. The acquisition included clinical-stage CD19/BCMA CAR-T candidate (TPST-2003) with a planned BLA filing in China for 2027. An investment commitment from Factor extended Tempest's operational runway to mid-2027. Existing Tempest shareholders retained approximately 35% of the pro forma company.

3Erigen LLC
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-11-19
Description

Jointly with Factor Bioscience, Erigen LLC sold dual-targeting CAR-T programs to Tempest Therapeutics in an all-stock transaction. The combined asset sale with Factor formed the basis of Tempest's strategic pivot and CAR-T expansion strategy.

in.investing.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Vertex Pharmaceuticals has built a significant cell therapy and regenerative medicine franchise including DMD programs following its acquisition of Alpine Immune Sciences. It competes with Factor's DMD gene-edited cell therapy efforts as a much larger and better-capitalized player.

TypeDirect peer
Description

Century Therapeutics develops iPSC-derived allogeneic cell therapies including engineered NK and T-cell candidates with gene-editing modifications. It is one of the closest direct peers to Factor's allogeneic, gene-edited iPSC platform approach.

TypeBroad incumbent
Description

Editas Medicine is a clinical-stage gene-editing company developing CRISPR-based therapeutics including ex vivo cell therapies. It is a broader incumbent in the gene-editing space that Factor competes with for talent, capital, and partnerships.

TypeDirect peer
Description

Caribou Biosciences is a clinical-stage CRISPR genome-editing company developing allogeneic CAR-T cell therapies. It is a direct peer in the intersection of gene editing and cell therapy that defines Factor Bioscience's core platform.

TypeDirect peer
Description

Fate Therapeutics is a clinical-stage iPSC-derived cell therapy company developing off-the-shelf NK and T-cell candidates for cancer and autoimmune disease. It directly parallels Factor Bioscience's iPSC platform approach to allogeneic cell therapy and competes for the same licensing and partnership ecosystem.

6Carisma Therapeutics
TypeEmerging player
Description

Carisma Therapeutics is developing engineered macrophage cell therapies (CAR-M) for solid tumors. Its macrophage-focused approach directly parallels Factor's FACT-112 IL12-expressing iMacrophage program and represents an emerging competitor in macrophage-based oncology cell therapy.

TypeBroad incumbent
Description

Beam Therapeutics is a clinical-stage base-editing company with cell therapy and in vivo programs. It is a broader incumbent in precision gene editing relevant to Factor's platform technology stack.

TypeDirect peer
Description

Lineage Cell Therapeutics is an allogeneic cell therapy developer and is Factor's active collaboration partner, holding an option to license Factor's hypoimmune iPSC cell line. It is a direct peer in cell therapy development and a meaningful commercial counterpart for Factor's platform.

TypeDirect peer
Description

Sana Biotechnology develops hypoimmune-modified cell therapies and in vivo gene editing/cell engineering approaches. It shares Factor's focus on reducing immunogenicity to enable off-the-shelf cell therapies and pursues a similar platform-plus-pipeline model.

TypeDirect peer
Description

Lyell Immunopharma develops next-generation cell therapies for solid tumors, with programs focused on T-cell exhaustion resistance and tumor microenvironment modulation. It overlaps with Factor's solid tumor programs such as FACT-112 iMacrophages.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Factor Bioscience

Regenerative Medicine Cell Therapyfactorbio.com

Factor Bioscience is a pre-clinical Cambridge, Massachusetts biotechnology company developing gene-edited cell therapies on a patented mRNA, cell-reprogramming, and gene-editing platform, targeting solid tumors, muscular dystrophy, and neurodegenerative disorders via licensing and partnerships.

What Factor Bioscience does

Factor Bioscience Inc. is a privately held, pre-clinical biotechnology company headquartered in Cambridge, Massachusetts, founded in 2011 with 1-10 employees. The company develops gene-edited cell therapies built on an integrated platform of patented mRNA, cell-reprogramming, and gene-editing technologies developed over approximately 15 years. Its active programs include FACT-112, an IL12-expressing iMacrophage candidate designed to repolarize immunosuppressive tumor microenvironments in solid tumors such as ovarian cancer; iPSC-derived mesenchymal stem cells targeting muscular dystrophy and neurodegenerative disorders; and gene-edited hypoimmune iPSC cell lines designed to reduce immunogenicity across cell therapy indications.

The company's scientific activities are evidenced by seven presentations at the ASGCT 29th Annual Meeting (Boston, May 2026) and pre-clinical data at ISCT 2026 (Dublin). In February 2026, Factor divested four dual-targeting CAR-T programs, including the clinical-stage CD19/BCMA candidate TPST-2003, to Tempest Therapeutics in an all-stock transaction, with co-founder Dr. Matt Angel departing to become President and CEO of Tempest. Factor retains operational independence and continues to advance the remaining platform programs.

Factor Bioscience operates as a technology licensor and platform provider rather than a direct commercial developer. Revenue mechanics consist of non-dilutive grant funding (including a U.S. Department of Defense grant awarded in January 2024 for Duchenne muscular dystrophy research) and partnership milestone/option payments (including a success payment from Lineage Cell Therapeutics in January 2026 tied to a hypoimmune iPSC cell line delivery). Pricing is not publicly disclosed and the company is pre-revenue, with no disclosed institutional venture financing. Customers and partners to date include the U.S. Department of Defense, Lineage Cell Therapeutics, and Tempest Therapeutics.

Factor Bioscience firmographics

Firmographics
Name
Factor Bioscience
Legal name
Factor Bioscience Inc.
Website
https://factorbio.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
Factor Bioscience is a pre-clinical Cambridge, Massachusetts biotechnology company developing gene-edited cell therapies on a patented mRNA, cell-reprogramming, and gene-editing platform, targeting solid tumors, muscular dystrophy, and neurodegenerative disorders via licensing and partnerships.
Ownership category
akta.pro rank

Factor Bioscience industry classification

Industry
Product category
Regenerative Medicine Cell Therapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Gene-editing technology
  • MRNA cell engineering
  • IPSC cell therapy
  • Regenerative medicine
  • Cell reprogramming

Where Factor Bioscience is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Factor Bioscience business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

Distribution channels1 record

Marketing channels1 record

Factor Bioscience product offering

Product offering

Core offering

Factor Bioscience develops an integrated platform of patented mRNA, cell-reprogramming, and gene-editing technologies for creating scalable, off-the-shelf gene-edited cell therapies. Its pipeline includes IL12-expressing iMacrophages (FACT-112) for solid tumors, iPSC-derived mesenchymal stem cells for muscular dystrophy and neurodegenerative disorders, dual-targeting CAR-T programs, and hypoimmune iPSC cell lines licensed to partners.

Product overview

Factor Bioscience is a Cambridge, Massachusetts-based biotechnology company that has developed a proprietary platform of patented mRNA, cell-reprogramming, and gene-editing technologies. The company operates multiple engineered cell therapy programs including: FACT-112 (IL12-expressing iMacrophages for solid tumors), iPSC-derived Mesenchymal Stem Cells for muscular dystrophy and neurodegenerative disorders, and Next-Generation CAR-T Approaches featuring dual-targeting technologies. The platform is built on 15 years of development in RNA-enabled cell engineering, with off-the-shelf cell therapy capabilities. The company also developed hypoimmune iPSC cell lines through partnerships.

Differentiator

Problem solved

Functional benefit

Products and services

  • FACT-112 (IL12-expressing iMacrophages)
  • iPSC-derived Mesenchymal Stem Cells
  • Next-Generation Dual-Targeting CAR-T Programs
  • RNA-Enabled Cell Engineering Platform
  • Gene-Edited Hypoimmune iPSC Cell Line

Quantifiable outcome

  • 100% complete response rate observed in CAR-T-naïve patients treated with TPST-2003 across REDEEM-1 and POEMS-1 trials (data generated by acquirer Tempest Therapeutics)
  • +1 more outcomes

Companies that use Factor Bioscience

Customer profile

Segments4 records

Ideal customer profiles2 records

Factor Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Factor Bioscience partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Lineage Cell TherapeuticscoreStrategic or Co-development Partner · 6 January 2026Strategic collaboration where Lineage Cell Therapeutics received a novel gene-edited hypoimmune iPSC cell line from Factor Bioscience. Acceptance of the cell line triggered a success payment from Lineage to Factor. Lineage retains an option to obtain an exclusive license for preclinical, clinical, and commercial use of the cell line. The cell line contains specific edits designed to reduce immunogenicity and prevent adverse immune responses across a range of cell therapy indications.
  • Tempest TherapeuticscoreStrategic or Co-development Partner · 19 November 2025All-stock acquisition of four dual-targeting CAR-T programs from Factor Bioscience and Erigen LLC by Tempest Therapeutics. Following the transaction, Factor's co-founder Dr. Matt Angel became President and CEO of Tempest. The acquisition included clinical-stage CD19/BCMA CAR-T candidate (TPST-2003) with a planned BLA filing in China for 2027. An investment commitment from Factor extended Tempest's operational runway to mid-2027. Existing Tempest shareholders retained approximately 35% of the pro forma company.
  • Erigen LLCminorStrategic or Co-development Partner · 19 November 2025Jointly with Factor Bioscience, Erigen LLC sold dual-targeting CAR-T programs to Tempest Therapeutics in an all-stock transaction. The combined asset sale with Factor formed the basis of Tempest's strategic pivot and CAR-T expansion strategy.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Factor Bioscience competitors and assessment

Company assessment

Broad incumbents

  • Vertex Pharmaceuticals: Vertex Pharmaceuticals has built a significant cell therapy and regenerative medicine franchise including DMD programs following its acquisition of Alpine Immune Sciences. It competes with Factor's DMD gene-edited cell therapy efforts as a much larger and better-capitalized player.
  • Editas Medicine: Editas Medicine is a clinical-stage gene-editing company developing CRISPR-based therapeutics including ex vivo cell therapies. It is a broader incumbent in the gene-editing space that Factor competes with for talent, capital, and partnerships.
  • Beam Therapeutics: Beam Therapeutics is a clinical-stage base-editing company with cell therapy and in vivo programs. It is a broader incumbent in precision gene editing relevant to Factor's platform technology stack.

Direct peers

  • Century Therapeutics: Century Therapeutics develops iPSC-derived allogeneic cell therapies including engineered NK and T-cell candidates with gene-editing modifications. It is one of the closest direct peers to Factor's allogeneic, gene-edited iPSC platform approach.
  • Caribou Biosciences: Caribou Biosciences is a clinical-stage CRISPR genome-editing company developing allogeneic CAR-T cell therapies. It is a direct peer in the intersection of gene editing and cell therapy that defines Factor Bioscience's core platform.
  • Fate Therapeutics: Fate Therapeutics is a clinical-stage iPSC-derived cell therapy company developing off-the-shelf NK and T-cell candidates for cancer and autoimmune disease. It directly parallels Factor Bioscience's iPSC platform approach to allogeneic cell therapy and competes for the same licensing and partnership ecosystem.
  • Lineage Cell Therapeutics: Lineage Cell Therapeutics is an allogeneic cell therapy developer and is Factor's active collaboration partner, holding an option to license Factor's hypoimmune iPSC cell line. It is a direct peer in cell therapy development and a meaningful commercial counterpart for Factor's platform.
  • Sana Biotechnology: Sana Biotechnology develops hypoimmune-modified cell therapies and in vivo gene editing/cell engineering approaches. It shares Factor's focus on reducing immunogenicity to enable off-the-shelf cell therapies and pursues a similar platform-plus-pipeline model.
  • Lyell Immunopharma: Lyell Immunopharma develops next-generation cell therapies for solid tumors, with programs focused on T-cell exhaustion resistance and tumor microenvironment modulation. It overlaps with Factor's solid tumor programs such as FACT-112 iMacrophages.

Emerging players

  • Carisma Therapeutics: Carisma Therapeutics is developing engineered macrophage cell therapies (CAR-M) for solid tumors. Its macrophage-focused approach directly parallels Factor's FACT-112 IL12-expressing iMacrophage program and represents an emerging competitor in macrophage-based oncology cell therapy.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Factor Bioscience social profiles

Digital presence

Factor Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Factor Bioscience leadership team

Management profile

Number of profiles

Profiles1 record

Factor Bioscience funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Factor Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Factor Bioscience

What does Factor Bioscience do?

Factor Bioscience develops an integrated platform of patented mRNA, cell-reprogramming, and gene-editing technologies for creating scalable, off-the-shelf gene-edited cell therapies. Its pipeline includes IL12-expressing iMacrophages (FACT-112) for solid tumors, iPSC-derived mesenchymal stem cells for muscular dystrophy and neurodegenerative disorders, dual-targeting CAR-T programs, and hypoimmune iPSC cell lines licensed to partners.

Is Factor Bioscience a public or private company?

Factor Bioscience is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Factor Bioscience founded?

Factor Bioscience was founded in 2011. It employs 11 to 50 people.

Where is Factor Bioscience based?

Factor Bioscience is headquartered in Cambridge, United States, in the North America region.

Who are Factor Bioscience's main competitors?

Broad incumbents on record are Vertex Pharmaceuticals, Editas Medicine and Beam Therapeutics. Direct peers are Century Therapeutics, Caribou Biosciences, Fate Therapeutics, Lineage Cell Therapeutics, Sana Biotechnology and Lyell Immunopharma. Carisma Therapeutics is listed as an emerging player.

Does Factor Bioscience have an API?

No public API is recorded for Factor Bioscience.

What industry is Factor Bioscience in?

Factor Bioscience's product category is Regenerative Medicine Cell Therapy. Its primary akta.pro industry code is HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Stock TitanTempest Q1 2026 loss $27.7M after CAR-T asset buyTempest Therapeutics reported a Q1 2026 net loss of $27.7 million, driven primarily by a $22.1 million acquired in-process R&D charge from a strategic asset acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. and Erigen LLC completed in February 2026. The company's cash position declined to $1.8 million as of March 31, 2026, from $7.7 million at year-end 2025. The company also announced positive interim clinical data showing a 100% complete response rate in 15 CAR-T-naïve patients treated with TPST-2003 across its REDEEM-1 and POEMS-1 trials, and selected Cincinnati Children's Applied Gene and Cell Therapy Center as its lead manufacturing partner for the therapy.AijournFactor Bioscience to Deliver Seven Presentations at the American Society of Gene & Cell Therapy (ASGCT) 29th Annual MeetingFactor Bioscience Inc., a Cambridge-based biotechnology company, announced its participation in the American Society of Gene & Cell Therapy 29th Annual Meeting in Boston from May 11-15, 2026, where it will deliver seven presentations covering preclinical data from its engineered cell therapy programs and cell engineering platforms. The presentations will showcase next-generation CAR-T approaches, RNA-enabled cell engineering technologies, and new programs including IL12-expressing iMacrophages for solid tumors and iPSC-derived mesenchymal stem cells for muscular dystrophy and neurodegenerative disorders. The company highlighted that these presentations reflect 15 years of platform development in gene-editing and cell therapy technologies.PR NewswireFactor Bioscience to Deliver Seven Presentations at the American Society of Gene & Cell Therapy (ASGCT) 29th Annual MeetingFactor Bioscience Inc., a Cambridge-based biotechnology company, announced its participation in the American Society of Gene & Cell Therapy 29th Annual Meeting to be held in Boston from May 11-15, 2026, where it will deliver seven presentations covering preclinical data from its engineered cell therapy programs. The presentations will showcase advances in next-generation CAR-T approaches, RNA-based cell engineering technologies, and off-the-shelf cell therapies, including data from IL12-expressing iMacrophages for solid tumors and novel iPSC-derived programs for muscular dystrophy and neurodegenerative disorders. The company stated that these presentations reflect 15 years of platform development aimed at developing therapeutics to treat intractable diseases.PR NewswireFactor Bioscience to Showcase Engineered iMacrophages (FACT-112) Targeting Ovarian Cancer In Vivo at ISCT 2026Factor Bioscience Inc. announced its participation in the International Society for Cell & Gene Therapy 2026 Annual Meeting in Dublin, Ireland, where it will present pre-clinical data on FACT-112, its IL12-expressing iMacrophage program for treating solid tumors including ovarian cancer. The in vivo data demonstrates that the engineered iMacrophages can repolarize the immunosuppressive tumor microenvironment and elicit immune-mediated tumor rejection. The company's CEO called the anti-tumor activity demonstrated a major milestone toward translating the gene-editing platform into clinically meaningful therapies.Stock TitanTempest names CEO, ends 2025 with $7.7M cashTempest Therapeutics reported year-end 2025 financial results showing a net loss of $26.3 million and cash position of $7.7 million, down from $30.3 million at the end of 2024, reflecting significant cash consumption from operations. The clinical-stage biotechnology company completed a strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. and announced positive interim data from its REDEEM-1 Phase 1/2a trial of TPST-2003, reporting a 100% complete response rate among six evaluable patients with relapsed/refractory multiple myeloma.BioSpaceTempest Reports Year End 2025 Financial Results and Provides Business UpdateTempest Therapeutics reported 2025 financial results and business updates, including the completion of a strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. and positive interim data from the REDEEM-1 Phase 1/2a trial showing a 100% complete response rate among six efficacy-evaluable patients with relapsed/refractory multiple myeloma treated with TPST-2003. The company ended 2025 with $7.7 million in cash, down from $30.3 million at the end of 2024, while its net loss improved to $26.3 million from $41.8 million year-over-year.BioSpaceTempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T AssetsTempest Therapeutics closed its previously announced acquisition of dual-targeting CAR-T programs from Factor Bioscience in an all-stock transaction, following stockholder approval on January 27, 2026. The acquisition brings Tempest a clinical-stage CD19/BCMA CAR-T candidate (TPST-2003) with a planned BLA filing in China for 2027, and extends the company's operational runway to mid-2027 with multiple potential value-generating milestones ahead.Business Wire BlogLineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor BioscienceLineage Cell Therapeutics announced the receipt of a novel gene-edited hypoimmune induced pluripotent stem cell (iPSC) line from Factor Bioscience Inc., marking a successful milestone in their strategic collaboration. The acceptance of the cell line triggered a success payment from Lineage to Factor, with Lineage retaining an option to obtain an exclusive license for preclinical, clinical, and commercial use. The cell line contains specific edits designed to reduce immunogenicity and prevent adverse immune responses, with potential application across a range of cell therapy indications.GlobeNewswireTempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027Tempest Therapeutics agreed to acquire Factor Bioscience's dual-CAR T programs in an all-stock deal expected to close in early 2026. The acquisition expands its pipeline and, with existing cash and an investment commitment, extends its runway to mid-2027. The company plans to pursue business development discussions or additional financing to advance amezalpat in first-line liver cancer.GlobeNewswireTempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027Tempest Therapeutics agreed to acquire Factor Bioscience's dual-CAR T programs in an all-stock deal, with closing expected in early 2026. The acquisition expands its pipeline and, combined with an investment commitment, is projected to extend its cash runway to mid-2027. Matt Angel will become CEO upon closing.